EORTC肺癌组关于NSCLC同步寡转移定义的问卷调查
该调查由EORTC肺癌组/同步寡转移定义共识组发放,回收444份回答,其中放疗科医生占55%。多数医生(81%)以治愈为目标,82%将根治性治疗意图纳入定义,但转移数目和器官数阈值分歧较大。脑MRI和PET/CT是主要分期手段,首选主要终点为总生存。
要点
- 81%医生以治愈同步寡转移NSCLC为目标,82%将根治意图纳入定义
- 转移数目阈值分歧:12%选1个,42%选≤3个,17%选≥5个
- 80%认为仅≤3个受累器官(不含原发)应纳入定义
核心结论
- 虽获得部分共识性回答,但同步寡转移定义仍有多项问题未解决,需进一步研究达成一致。
研究设计与样本
- EORTC肺癌组/同步寡转移定义共识组在欧洲发放问卷调查,共分析444份回答,放疗科医生占55%(n=242),呼吸科医生占15%(n=66),肿瘤内科医生占14%(n=64)。
主要发现
- 361名医生(81%)以治愈同步寡转移NSCLC患者为目标,82%(n=362)将根治性治疗意图纳入同步寡转移定义。
- 同步寡转移定义中考虑的最大转移数目各异:12%回答1个转移,42%回答≤3个,17%回答≥5个转移。
- 79%(n=353)认为受累器官数目对定义重要,其中80%(n=355)认为仅≤3个受累器官(不含原发)应纳入定义。
- 317名(72%)将纵隔淋巴结受累纳入定义,其中22%(n=70/317)将纵隔淋巴结计为转移部位。
- 多数医生完成分期时使用脑磁共振成像(91%,n=403)和正电子发射断层扫描/计算机断层扫描(98%,n=437)。
关键数值与推荐
- 315名(71%)医生要求转移病灶经病理证实方可定义同步寡转移。
- 同步寡转移临床试验的首选主要终点为总生存(73%,n=325)。
临床怎么用
- 临床定义同步寡转移NSCLC时需综合转移数目、受累器官数(多数支持≤3个)及纵隔淋巴结是否计入转移部位。
- 分期评估应包含脑MRI和PET/CT,并考虑对转移病灶进行病理证实。
- 设计同步寡转移临床试验时,总生存是多数医生认可的主要终点。
局限性
- 调查结果反映医生偏好而非患者结局证据,且转移数目和器官数阈值等关键定义要素仍存在分歧,未达成最终共识。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non-small-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting. METHODS: A European Organisation for Research and Treatment of Cancer Lung Cancer Group (LCG)/sOM-d consensus group survey was distributed to LCG, sOM-d consensus group, and several European thoracic oncology societies' members. RESULTS: 444 responses were analysed (radiation oncologist: 55% [n = 242], pulmonologist: 15% [n = 66], medical oncologist: 14% [n = 64]). 361 physicians (81%) aimed to cure sOM NSCLC patients and 82% (n = 362) included the possibility of radical intent treatment in their sOM-d. The maximum number of metastases considered in sOM-d varied: 12% replied 1 metastasis, 42% ≤ 3, and 17% ≥ 5 metastases. 79% (n = 353) stated that number of organs involved was important for sOM-d, and most (80%, n = 355) considered that only ≤3 involved organs (excluding primary) should be included. 317 (72%) included mediastinal lymph node involvement in the sOM-d and 22% (n = 70/317) counted mediastinal lymph node as a metastatic site. Most physicians completed sOM staging with brain magnetic resonance imaging (91%, n = 403) and positron emission tomography/computed tomography (98%, n = 437). Pathology proof of metastatic disease was a requirement to define sOM for 315 (71%) physicians. The preferred primary outcome for sOM clinical trials was overall survival (73%, n = 325). CONCLUSION: Although consensual answers were obtained, several issues remain unresolved and will require further research to agree on a sOM-d.
引用
- Levy A, Hendriks LEL, Berghmans T, et al. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. Eur J Cancer. 2019. PMID: 31671363. doi:10.1016/j.ejca.2019.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。